{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T11:04:13Z","timestamp":1748084653790,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s11255-019-02351-7","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T18:03:26Z","timestamp":1575914606000},"page":"121-128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Adjunctive acetazolamide therapy for the treatment of Bartter syndrome"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2942-4280","authenticated-orcid":false,"given":"Mojgan","family":"Mazaheri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5202-036X","authenticated-orcid":false,"given":"Farahnak","family":"Assadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1652-6237","authenticated-orcid":false,"given":"Simin","family":"Sadeghi-Bojd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"2351_CR1","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/0002-9343(62)90214-0","volume":"33","author":"FC Bartter","year":"1962","unstructured":"Bartter FC, Pronove P, Gill JR, MacCardle RC (1962) Hyperplasia of juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis: a new syndrome. Am J Med 33:811\u2013828","journal-title":"Am J Med"},{"key":"2351_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/IJNRD.S155397","volume":"11","author":"TDS Cunha","year":"2018","unstructured":"Cunha TDS, Heilberg IP (2018) Bartter syndrome: causes, diagnosis, and treatment. Int J Nephrol Renovasc Dis 11:291\u2013301","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2351_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/MOP.0000000000000447","volume":"29","author":"HW Seyberth","year":"2017","unstructured":"Seyberth HW, Weber S, Komhoff M (2017) Bartter\u2019s and Gitelman\u2019s syndrome. Curr Opin Pediatr 29:179\u2013186","journal-title":"Curr Opin Pediatr"},{"key":"2351_CR4","first-page":"77","volume":"89","author":"FC Batter","year":"1976","unstructured":"Batter FC, Gill JR, Frolich JC, Bowden RE, Taylor AA, Keiser HR et al (1976) Prostaglandins are overproduced by the kidney and mediate hyperreninemia in Bartter\u2019s syndrome. Trans Assoc Am Phys. 89:77\u201391","journal-title":"Trans Assoc Am Phys."},{"key":"2351_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00424-008-0498-1","volume":"456","author":"M Boone","year":"2008","unstructured":"Boone M, Dean PMT (2008) Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption. Pflugers Arch 456:1005\u20131024","journal-title":"Pflugers Arch"},{"key":"2351_CR6","doi-asserted-by":"publisher","first-page":"F1143","DOI":"10.1152\/ajprenal.00396.2011","volume":"301","author":"GR Ares","year":"2011","unstructured":"Ares GR, Gaceres PS, Ortiz PA (2011) Molecular regulation of NKCC2 in the thick ascending limb. Am J Physiol Renal Physiol 301:F1143\u2013F1159","journal-title":"Am J Physiol Renal Physiol"},{"key":"2351_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/ng0696-183","volume":"13","author":"DB Simon","year":"1996","unstructured":"Simon DB, Karet FE, Hamdam JM, DiPietro A, Sanjad SA, Lifton RP (1996) Bartter\u2019s syndrome, hypokalemic alkalosis with hypercalciuria, is caused by mutations in the Na\u2013K\u20132Cl cotransporter NKCC2. Nat Genet 13:183\u2013188","journal-title":"Nat Genet"},{"key":"2351_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/boc.201100049","volume":"104","author":"M Carmosino","year":"2012","unstructured":"Carmosino M, Procino G, Svelto M (2012) Na+ -K+ -2Cl\u2013cotransporter type 2 trafficking and activity: the role of interacting proteins. Bil Cell 104:201\u2013221","journal-title":"Bil Cell"},{"key":"2351_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/ng1096-152","volume":"14","author":"DB Simon","year":"1996","unstructured":"Simon DB, Karet EE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H et al (1996) Genetic heterogeneity of Bartter\u2019s syndrome revealed by mutations in the K+ channel, ROMK. Nati Genet 14:152\u2013156","journal-title":"Nati Genet"},{"key":"2351_CR10","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1681\/ASN.2016101057","volume":"28","author":"E Seyes","year":"2017","unstructured":"Seyes E, Andrini O, Kecj M, Mansour-Hendill L, Courand PY, Simin C et al (2017) Clinical and genetic spectrum of Bartter syndrome type 3. J Am Soc Nephrol 28:2540\u20132552","journal-title":"J Am Soc Nephrol"},{"key":"2351_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng1097-171","volume":"117","author":"DB Simon","year":"1997","unstructured":"Simon DB, Binda RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R et al (1997) Mutations in the chloride channel gene, CLCNKB, cause Bartter\u2019s syndrome type 111. Nat Genet 117:171\u2013178","journal-title":"Nat Genet"},{"key":"2351_CR12","first-page":"206","volume":"22","author":"B Dane","year":"2007","unstructured":"Dane B, Yayla M, Dane C (2007) Prenatal diagnosis of Bartter syndrome with biochemical examination of amniotic fluid: case report Fetal Diag Ther 22:206\u2013208","journal-title":"Prenatal diagnosis of Bartter syndrome with biochemical examination of amniotic fluid: case report Fetal Diag Ther"},{"key":"2351_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/MNH.0000000000000346","volume":"26","author":"M Komhoff","year":"2017","unstructured":"Komhoff M, Laghmani K (2017) Pathophysiology of antenatal Bartter\u2019s syndrome. Curr Opin Nephrol Hypertens 26:419\u2013425","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2351_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13023-018-0981-5","volume":"14","author":"M Najafi","year":"2019","unstructured":"Najafi M, Koerdi-Tamandani DM, Behjati F, Sadeghi-Bojd S, Bakey Z, Karimiani EG et al (2019) Mimicry and well known genetic friends: molecular diagnosis in an Iranian cohort of suspected Batter syndrome and proposition of an algorithm for clinical differential diagnosis. Orphanet J Rare Dis 14:41. https:\/\/doi.org\/10.1186\/s13023-018-0981-5","journal-title":"Orphanet J Rare Dis"},{"key":"2351_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng752","volume":"29","author":"R Brikenhager","year":"2001","unstructured":"Brikenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz I et al (2001) Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29:310\u2013314","journal-title":"Nat Genet"},{"key":"2351_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/jmg.2007.052944","volume":"45","author":"K Nozu","year":"2008","unstructured":"Nozu K, Inagaki T, Fu XJ, Nozu Y, Kaito H, Kanda K et al (2008) Molecular analysis of digenetic inheritance in Bartter syndrome with sensonrineual deafness. J Med Genet 45:182\u2013186","journal-title":"J Med Genet"},{"key":"2351_CR17","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMoa1507629","volume":"374","author":"K Laghmani","year":"2016","unstructured":"Laghmani K, Beck BB, Yang S-S, Seaayfan E, Wenzel A, Reusch B et al (2016) Polyhydramnios, transient antenatal Bartter\u2019s syndrome, and MAGED2 mutations. N Engl J Med 374:1853\u20131863","journal-title":"N Engl J Med"},{"key":"2351_CR18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0140-6736(02)09842-2","volume":"360","author":"S Watanable","year":"2002","unstructured":"Watanable S, Fukumoto S, Chang H, Takeuch Y, Hasegawa Y, Okazaki R et al (2002) Association between activating mutations of calcium-sensing receptor and Bartter\u2019s syndrome. Lancet 360:692\u2013694","journal-title":"Lancet"},{"key":"2351_CR19","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00467-018-4135-8","volume":"34","author":"G Gasongo","year":"2019","unstructured":"Gasongo G, Greebaum LA, Neil O, Kwon T, Macher MA, Maisin A et al (2019) Effect of nonsteroidal anti-inflammatory drugs in children with Bartter syndrome. Pediatr Nephrol 34:679\u2013684","journal-title":"Pediatr Nephrol"},{"key":"2351_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1046\/j.1523-1755.2002.00435.x","volume":"62","author":"SC Reinalter","year":"2002","unstructured":"Reinalter SC, Jecj N, Brochhausen C, Watzer B, Nusing RM, Seyberth HW et al (2002) Role of cyclooxygenase-2 in hyperprostaglandin E syndrome\/antenatal Bartter syndrome. Kidney Int 62:253\u2013260","journal-title":"Kidney Int"},{"key":"2351_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jped.2014.01.012","volume":"90","author":"CLP Nascimento","year":"2014","unstructured":"Nascimento CLP, Garcia CL, Schvartsman BGS, Vaisbich MH (2014) Treatment of Bartter syndrome, unsolved issue. J Pediatr 90:512\u2013517","journal-title":"J Pediatr"},{"key":"2351_CR22","doi-asserted-by":"publisher","first-page":"858-563","DOI":"10.1007\/s00467-004-1527-8","volume":"19","author":"MH Vaisbich","year":"2004","unstructured":"Vaisbich MH, Fujimura MD, Koch VH (2004) Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol 19:858-563","journal-title":"Pediatr Nephrol"},{"key":"2351_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.amjcard.2006.07.069","volume":"99","author":"WB White","year":"2007","unstructured":"White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX et al (2007) Risk of cardiovascular events in patients receiving celecoxib: a metaanalysis of randomized clinical trials. Am J Cardiol 99:91\u201398","journal-title":"Am J Cardiol"},{"key":"2351_CR24","first-page":"136","volume":"10","author":"PA Preisig","year":"2005","unstructured":"Preisig PA, Toto RD, Alpern RJ (2005) Carbonic anhydrase inhibitors. Renal Physiol 10:136\u2013159","journal-title":"Renal Physiol"},{"key":"2351_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00246-005-1132-z","volume":"27","author":"F Assadi","year":"2005","unstructured":"Assadi F (2005) Acetazolamide for prevention of contrast-induce nephropathy: a new use for an old drug. Pediat Cardiol 27:238\u2013242","journal-title":"Pediat Cardiol"},{"key":"2351_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013663","journal-title":"J Am Soc Nephrol"},{"key":"2351_CR27","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","volume":"319","author":"DG Altman","year":"1999","unstructured":"Altman DG, Anderson PK (1999) Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319:1492\u20131495","journal-title":"BMJ"},{"key":"2351_CR28","first-page":"2671","volume-title":"Textbook of clinical pediatrics","author":"F Assadi","year":"2011","unstructured":"Assadi F (2011) A practical approach to metabolic alkalosis. In: Elzouki AY, Harfi HA, Nazer H (eds) Textbook of clinical pediatrics, 2nd edn. Springer, New York, pp 2671\u20132676","edition":"2"},{"key":"2351_CR29","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1177\/1060028013500468","volume":"47","author":"MG Andrews","year":"2013","unstructured":"Andrews MG, Johnson PN, Lammers EM, Harrison DL, Miller JL (2013) Acetazolamide in critically ill neonates with metabolic alkalosis. Ann Pharmacother 47:1130\u20131135","journal-title":"Ann Pharmacother"},{"key":"2351_CR30","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1097\/PCC.0000000000000971","volume":"17","author":"C Lopez","year":"2016","unstructured":"Lopez C, Alcaraz AJ, Toledo B, Cortejoso L, Gil-Ruitz MA (2016) Acetazolamide therapy for metabolic alkalosis in pediatric intensive care patients. Pediatri Crit Care Med 17:e551\u2013e555","journal-title":"Pediatri Crit Care Med"},{"key":"2351_CR31","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1053\/j.ajkd.2012.10.028","volume":"61","author":"AJ Peixoto","year":"2013","unstructured":"Peixoto AJ, Alpern RJ (2013) Treatment of severe metabolic alkalosis in a patient with congestive heart failure. Am J Kidney Dis 61:822\u2013827","journal-title":"Am J Kidney Dis"},{"key":"2351_CR32","doi-asserted-by":"publisher","first-page":"3e4-4","DOI":"10.1097\/PCC.0000000000000313","volume":"16","author":"A Bar","year":"2015","unstructured":"Bar A, Cies J, Stapleton K, Tauber D, Chopra A, Shore PM (2015) Acetazolamide therapy for metabolic alkalosis in critically ill pediatric patients. Pediatr Crit Care Med 16:3e4-4","journal-title":"Pediatr Crit Care Med"},{"issue":"9","key":"2351_CR33","doi-asserted-by":"publisher","first-page":"e0137163","DOI":"10.1371\/journal.pone.0137163","volume":"10","author":"B Zingerman","year":"2015","unstructured":"Zingerman B, Herman-Edelstein M, Eman A, Bar Sheshet Itach S, Ori Y, Rozen-Zvi B et al (2015) Effect of Acetazolamide on obesity-induced glomerular hyperfiltration: a randomized control trail. Plos One 10(9):e0137163. https:\/\/doi.org\/10.1371\/journal.pone.0137163","journal-title":"Plos One"},{"key":"2351_CR34","first-page":"99","volume":"15","author":"NL Yeyati","year":"1992","unstructured":"Yeyati NL, Alternberg GA, Adrogue HJ (1992) Mechanism of acetazolamide-induced rise in renal vascular resistance assessed in the dog whole kidney. Ren Physiol Biochem 15:99\u2013105","journal-title":"Ren Physiol Biochem"},{"key":"2351_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3109\/00365518909089139","volume":"49","author":"P Skott","year":"1989","unstructured":"Skott P, Hommel E, Bruun NE, Arnold-Larsen S, Parving HH (1989) Theacute effect of acetazolamide on glomerular filtration rate and proximal tubular reabsorption of sodium and water in normal man. Scand J Clin Lab Invest 49:583\u2013587","journal-title":"Scand J Clin Lab Invest"},{"key":"2351_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000169016","volume":"16","author":"LA Slomowitz","year":"1996","unstructured":"Slomowitz LA, Bergamo R, Hirschberg R, Grosvenor M, Kopple JD (1996) Enalapril attenuated the renal hemodynamic effect of acetazolamide in patients with diabetes mellitus: possible implications for tubuloglomerular feedback. Am J Nephrol 16:315\u2013319","journal-title":"Am J Nephrol"},{"key":"2351_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1042\/cs0810457","volume":"81","author":"T Hannedouche","year":"1991","unstructured":"Hannedouche T, Lazzo M, Delgado AG, Boilard C, Lacour B, Grunfeld JP (1991) Feedback mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients. Clin Sci 81:457\u2013464","journal-title":"Clin Sci"},{"key":"2351_CR38","first-page":"23","volume":"220","author":"M Galler","year":"1982","unstructured":"Galler M, Backenroth R, Folkert VW, Schlondorff D (1982) Effect of converting enzyme inhibitors on prostaglandin synthesis by isolated glomeruli and aortic strips from rats. J Pharmacol Exp Ther 220:23\u201328","journal-title":"J Pharmacol Exp Ther"},{"key":"2351_CR39","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1136\/bmj.283.6305.1527","volume":"283","author":"DN Maisey","year":"1981","unstructured":"Maisey DN, Brown RD (1981) Acetazolamide and symptomatic metabolic acidosis in mild renal failure. Br Med J 283:1527\u20131529","journal-title":"Br Med J"},{"key":"2351_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0002-9343(64)90150-0","volume":"36","author":"R Dorris","year":"1964","unstructured":"Dorris R, Olivia JV, Rodman T (1964) Dichlorphenamide, a potent carbonic anhydrase inhibitor: effect on alveolar ventilation, ventilation-perfusion relationships and diffusion in patients with chronic lung disease. Am J Med 36:79\u201386","journal-title":"Am J Med"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02351-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02351-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02351-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T01:09:18Z","timestamp":1607389758000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02351-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["2351"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02351-7","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"type":"print","value":"0301-1623"},{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2019,12,9]]},"assertion":[{"value":"12 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors acknowledge that the submitted article is original, has not been published previously in whole or part, and is not currently under review elsewhere. Authors further declare that there is no financial support or relationships that may pose conflict of interest regarding the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with ethical standards of the appropriate institutional research ethics committee on human experimentation and has been performed in accordance with the ethical standards as laid in the 1964 Declaration of Helsinki and its later amendments as revised in 2013 and followed the CONSORT 2010 checklist guidelines for reporting the randomized clinical trial (Clinical Trial Registration Reference: IR.ZAUMS.REC.1397.492).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written parental informed consent was obtained for all participants prior to the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}